Invivyd, Inc. (IVVD) is a clinical-stage biopharmaceutical company developing monoclonal antibody therapies for infectious diseases, most notably COVID-19. Current sell-side coverage is thin but unusually uniform. Three analysts have published current price targets, and all three stand at $10 per share: Thomas Shrader at BTIG (Buy, reiterated September 2026), Patrick Trucchio at H.C. Wainwright (Buy, reiterated September 2026), and Joshua Schimmer at Cantor Fitzgerald (Overweight, reiterated September 2026).
Because every verified target is identical at $10, the arithmetic mean is exactly $10, and the rounded central target is $10. There is no spread between the high and low targets among currently active ratings, which is unusual and worth noting: the uniformity means the average analyst price target reflects three firms converging on the same figure rather than a genuine range of opinion. An earlier downgrade by D. Boral Capital (to Hold in November 2025) is older and does not carry a current price target in the data reviewed.
Analysts' bullishness centers on VYD2311, the company's investigational low-dose intramuscular COVID-19 antibody, and the upcoming DECLARATION Phase 3 readout. It is important to stress that this $10 figure is the calculated mean of the verified targets, not a guarantee, and it implies a move far larger than is typical for an analyst forecast.
Shares of Invivyd have been trading near $0.59, down sharply from a 52-week range that reached roughly $3.07 at the high and about $0.53 at the low. Reaching a $10 target from around $0.59 implies an upside of approximately 1,600%, which must be classified as a very large move by any standard — well beyond a normal 12-month stock price forecast.
The path, as framed by analysts, rests almost entirely on clinical and regulatory milestones rather than current financials. The company reported roughly $14.3 million in revenue for the second quarter of 2026 against a GAAP (generally accepted accounting principles) net loss of about $44.4 million. Positive topline results from the LIBERTY Phase 3 study, announced in September 2026, showed VYD2311's safety and tolerability compared favorably with an mRNA COVID-19 vaccine, and the company plans to pursue a Biologics License Application under the FDA's accelerated approval pathway pending DECLARATION results.
From a technical standpoint, the stock sits near the low end of a steep multi-month downtrend, with the 52-week high around $3.07 acting as a distant reference point and recent trading compressed near the $0.53 to $0.60 zone. Any sustained recovery would first need to reclaim the psychological $1 level, which is far below the $10 target but still a meaningful support and resistance threshold for a stock trading under a dollar. The enormous gap between the current price and the target means the relevant resistance levels are more about avoiding delisting pressure than about charting a direct path to $10.
Analyst price targets generally reflect a research horizon of about 12 months, though the data reviewed here does not always specify an exact timeframe for each firm. Given the catalyst-driven nature of this stock, investors should watch the DECLARATION Phase 3 results, any BLA submission or FDA feedback, updates on PEMGARDA's full-approval pathway, quarterly cash burn and financing activity, and any Nasdaq delisting proceedings. These events, more than ordinary earnings cadence, will determine whether the share price can begin to close the very wide gap toward the $10 target.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. For a highly volatile, catalyst-driven name like Invivyd, these signals can help traders spot changing trends and potential turning points more efficiently than manual chart review. Traders can use them to discover new opportunities, monitor existing positions, and stay alert to shifts in momentum. Exploring the AI Daily Buy/Sell Signals page can provide an additional, data-driven layer to your market outlook.
The question of whether Invivyd can reach $10 is best understood as a clinical-binary proposition rather than a valuation exercise. The central target is the arithmetic mean of three verified analyst targets, all set at $10, and it implies a required move of roughly 1,600% from the recent price near $0.59 — a very large move by any measure. Support rests on a favorable DECLARATION readout and an accelerated approval pathway for VYD2311, while the principal obstacles are continued losses, the PEMGARDA authorization expiry, and delisting risk. Analyst coverage is unanimous at $10, which provides conviction but little diversity of opinion. Investors should monitor the pivotal trial data and regulatory developments rather than treat the target as a probability. No outcome is guaranteed.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, IVVD has been loosely correlated with BCTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IVVD jumps, then BCTX could also see price increases.
| Ticker / NAME | Correlation To IVVD | 1D Price Change % | ||
|---|---|---|---|---|
| IVVD | 100% | -3.66% | ||
| BCTX - IVVD | 43% Loosely correlated | -1.07% | ||
| IMMX - IVVD | 36% Loosely correlated | -2.57% | ||
| CANF - IVVD | 35% Loosely correlated | -1.19% | ||
| HCWB - IVVD | 35% Loosely correlated | -0.42% | ||
| AXON - IVVD | 34% Loosely correlated | -0.21% | ||
More | ||||